<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The relationship between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding, epithelial-mesenchymal transition (EMT) protein expression, and survival has not been closely examined in <z:e sem="disease" ids="C0677948" disease_type="Neoplastic Process" abbrv="">stage II colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to assess proteins implicated in EMT and to correlate their expression with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding, microsatellite status, and survival </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A total of 258 stage II <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> were identified (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding characterized in 122 cases) </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemistry for LAMC2, E cadherin, cathepsin L, and β catenin using tissue microarrays was performed </plain></SENT>
<SENT sid="4" pm="."><plain>EMT and mismatch repair (MMR) protein expression were correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding and survival </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: LAMC2 positivity (P &lt; .001) and low membranous β catenin (P = .056) were associated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding </plain></SENT>
<SENT sid="6" pm="."><plain>In a univariate survival analysis, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding (P &lt; .001), LAMC2 positivity (P &lt; .03), and stromal cytoplasmic cathepsin L (P = .025) predicted poorer prognosis </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analysis showed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding to be the only variable independently associated with survival: hazard ratio = 7.9 (95% confidence interval = 3-21); P &lt; .001 </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> budding was more frequent in microsatellite-stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) versus microsatellite-instable (MSI) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>: 48% versus 26%, respectively; P = .087 </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> cases exhibited reduced membranous β catenin (P = .002) and increased cytoplasmic and nuclear β catenin (P &lt; .001) compared with MSI cases </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Epithelial mesenchymal protein expression plays a key role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> budding and prognosis in early-stage <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and requires further evaluation </plain></SENT>
</text></document>